Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
A look at big oncology deals since 2016 finds outright success stories hard to come by.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.